Stocky turns companies like Takeda Pharmaceutical Co., Ltd. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. TKPHF scores below 50 across Growth (38.7) and Value (40.0) metrics, with Leadership Alignment at 52—suggesting founder incentives are only moderately tied to shareholder returns. At 38.3x forward P/E, valuation is stretched relative to modest compounder fundamentals; the Vulnerability Profile offers only adequate financial breathing room, leaving little margin for error.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Takeda Pharmaceutical Co., Ltd.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 45/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Takeda Pharmaceutical Co., Ltd. (TKPHF) at 45/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. TKPHF scores below 50 across Growth (38.7) and Value (40.0) metrics, with Leadership Alignment at 52—suggesting founder incentives are only moderately tied to shareholder returns. At 38.3x forward P/E, valuation is stretched relat
TKPHF's current Stocky Verdict is 45/100, placing it in the "Cautious" band. This composite combines a 40/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Takeda Pharmaceutical Co., Ltd. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Takeda Pharmaceutical Co., Ltd. scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Takeda Pharmaceutical Co., Ltd.'s Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Takeda Pharmaceutical Co., Ltd..
Sign up free and unlock the full analysis on TKPHF — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TKPHF in the app.
